3 Stocks I Saw on T...
Health Care: Drugs
Teva Pharmaceutical Industries Ltd (TEVA: NASDAQ)
$44.66 -0.28 | -0.62%
02/09/12 - 04:00 PM ET
3.82M / 5.44M
Vol / Avg. Vol:44.91 / 44.94
Open / Prev. Close:44.60 - 45.15
Today's Range:35.00 - 52.35
52 Wk Range:11.35%
Performance YTD:TheStreet Rating:
Portfolios with TEVA
- Portfolio NameUser Type
- Contributor8 Pharma Stocks to Watch
- Userdividend
- UserIncome stocks
- UserWassmg Portfolio 1
- Usermkhanty999
- UserIncome
- ContributorHighest-Yielding Drug Stocks
- UserDec 2011
- UserRoly
- ContributorStocks Rising On Unusual Vo...
Latest TEVA Headlines from TheStreet
- Analysts' Actions: FDX, BWLD, GILD, MGM 02.06.12 | 09:02 am
- Teva Pharmaceutical Industries Management Presents At 30th Annual J.P. Morgan Healthcare Conference (Transcript) 01.24.12 | 10:01 am
- UBS: 8 Pharma Stocks to Watch 01.20.12 | 12:01 pm
- TheStreet Ratings Top 10 Rating Changes 01.17.12 | 04:01 pm
- Teva Gets Upgrade on Revenue Growth 01.11.12 | 10:01 am
- Teva Pharmaceutical Industries Ltd Stock Upgraded (TEVA) 01.11.12 | 06:01 am
- 'Mad Money Lightning Round': Biogen Shines 01.10.12 | 07:01 pm
- Teva's CEO Reviews Management Succession (Transcript) 01.03.12 | 03:01 pm
- Stocks to Watch: Chesapeake, BP, Halliburton 01.03.12 | 05:01 am
- Teva Taps Bristol-Myers' Levin as Next CEO 01.02.12 | 03:01 pm
Press Releases for TEVA
- Phase 1 Study Of OGX-427 Presented At The ASCO 2012 Genitourinary Cancers Symposium Shows Early Evidence Of Activity In Bladder Cancer - PR Newswire 02.02.12 | 08:02 am
- Clinical Data On OGX-427 Presented At The ASCO 2012 Genitourinary Cancers Symposium Provide Ongoing Evidence Of Hsp27 As A Potential Therapeutic Target In Advanced Prostate Cancer - PR Newswire 02.02.12 | 08:02 am
- Teva To Report Fourth Quarter And Full Year 2011 Financial Results On February 15, 2012 - Business Wire 01.16.12 | 11:01 pm
- Teva To Present At The 30th Annual J.P. Morgan Healthcare Conference - Business Wire 01.09.12 | 10:01 am
- OncoGenex Announces Publication Of Phase I/II Custirsen (OGX-011/TV-1011) Data In Journal Of Thoracic Oncology - PR Newswire 01.04.12 | 08:01 am
- Advanced Magnetic Resonance Imaging Technology Suggests Axonal Repair In Multiple Sclerosis Patients Treated With COPAXONE® - Business Wire 01.03.12 | 08:01 am
- Teva Announces Management Succession - Business Wire 01.01.12 | 11:01 pm
- Dr. Rob Koremans To Succeed Dr. Gerard Van Odijk As President And CEO Of Teva Europe - Business Wire 12.22.11 | 07:12 am
- Teva Provides 2012 Non-GAAP Financial Outlook; 2012 Non-GAAP Diluted EPS Of $5.48 To $5.68 - Business Wire 12.21.11 | 08:12 am
- Teva Announces $3 Billion Share Repurchase Program - Business Wire 12.21.11 | 07:12 am
Partner Headlines for TEVA
- 2 Biotechs On Teva's Radar Screen - Seeking Alpha 02.06.12 | 08:02 am
- 12 Healthcare Companies Expecting Major February Catalysts - Seeking Alpha 02.01.12 | 07:02 am
- 5 Cheap Stocks That Could Jump Higher In 2012 - Seeking Alpha 01.27.12 | 05:01 pm
- Label Expansion for Merck KGaA Drug - Analyst Blog - Zacks 01.27.12 | 04:01 pm
- Label Expansion for Merck KGaA Drug - Analyst Blog - Zacks 01.27.12 | 04:01 pm
- Zacks Bull and Bear of the Day Highlights: DaVita, Hhgregg, Mylan, Teva Pharmaceutical and Novartis - Press Releases - Zacks 01.25.12 | 09:01 am
- 12 Best Yielding Large Capitalized Stocks On NASDAQ - Seeking Alpha 01.22.12 | 09:01 am
- 5 Very Cheap Stocks Hiding In Plain Sight - Seeking Alpha 01.19.12 | 09:01 am
- Why TEVA's Recent Momentum Will Continue Throughout 2012 - Seeking Alpha 01.13.12 | 05:01 pm
- Biosimilars: The Next Big Thing - Analyst Blog - Zacks 01.13.12 | 05:01 pm
